glp-1 egfr cut off Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists GLP-1 receptor agonists' impact on

The International Diabetes Federation (IDF) estimated that 537 million adults were living with diabetes in 2021, and this number is projected to rise significantly in the coming years

Additionally, there was an average improvement in glycated hemoglobin levels of 0.8 point ( 0.6), highlighting the positive impact of the therapy

As agents such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) continue to deliver robust A1C reduction and double-digit weight loss, clinicians must balance metabolic gains with careful risk assessment

In the new study, a team led by Dr

Diabetes Obes Metab (2019) 21(2):23443